medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2016, Número 4

<< Anterior Siguiente >>

Rev Esp Med Quir 2016; 21 (4)


Enfermedad pulmonar crónica del recién nacido

Pezzotti RMÁ, Torres- Rodríguez A

Idioma: Español
Referencias bibliográficas: 37
Paginas: 155-164
Archivo PDF: 167.16 Kb.


RESUMEN

Este artículo hace un recuento de los aspectos más relevantes de clínica, fisiopatológía, elementos radiológicos de diagnóstico y estrategias de tratamiento de la insuficiencia respiratoria en recién nacidos que han reducido la enfermedad pulmonar crónica, así como acciones de apoyo básicas en estos pacientes, tales como la administración de líquidos, uso de esteroides, nutrición y varios fármacos con sus referencias bibliográficas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Weinstein MR, Peters ME, Sadek M, Palta M. A new radiographic scoring system for bronchopulmonary dysplasia. Newborn Lung Project. Pediatr Pulmonol. 1994 Nov; 18(5):284-9.

  2. Moya MP, Bisset GS 3rd, Auten RL Jr, Miller C, Hollingworth C, Frush DP. Reliability of CXR for the diagnosis of bronchopulmonary dysplasia. Pediatr Radiol. 2001 May;31(5):339-42.

  3. Choi CW, Kim BI, Kim HS, Park JD, Choi JH, Son DW. Increase of interleukin-6 in tracheal aspirate at birth: a predictor of subsequent bronchopulmonary dysplasia in preterm infants. Acta Paediatr. 2006;95(1):38–43.

  4. Oei J, Lui K, Wang H, Henry R. Decreased interleukin-10 in tracheal aspirates from preterm infants developing chronic lung disease. Acta Paediatr. 2002;91(11):1194–1199.

  5. Kevill KA, Bhandari V, Kettunen M, et al. A role for macrophage migration inhibitory factor in the neonatal respiratory distress syndrome. J Immunol. 2008;180(1):601–608.

  6. Cullen A, Van Marter LJ, Allred EN, Moore M, Parad RB, Sunday ME Urine bombesin-like peptide elevation precedes clinical evidence of bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2002 Apr 15;165(8):1093-7.

  7. Jobe AH, Kramer BW, Moss TJ, et al. Decreased indicators of lung injury withcontinuous positive expiratory pressure in preterm lambs. Pediatr Res 2002;52(3):387–92.

  8. Support Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG,et al. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010 May 27;362(21):1970-9. Epub 2010 May 16.

  9. Morley CJ, Davis PG, Doyle LW, Brion LP, Hascoet JM, Carlin JB; COIN Trial Investigators Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med. 2008 Feb 14;358(7):700-8.

  10. Henderson-Smart DJ, De Paoli AG, Clark RH, Bhuta T. High frequency oscillatory ventilation versus conventional ventilation for infants with severe pulmonary dysfunction born at or near term. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD002974.

  11. Cools F, Henderson-Smart DJ, Offringa M, Askie LM. Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants Cochrane 2009 Jul 8;(3):CD000104.

  12. Soll RF, Morley CJ. Prophylactic versus selective use of surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2001;(2):CD000510

  13. Saugstad OD. Oxygen toxicity in the neonatal period. Acta Pediatr Scand 1990;79:881–92.

  14. Stephens BE, Gargus RA, Walden RV, Mance M, Nye J, McKinley L, Tucker R, Vohr BR. Fluid regimens in the first week of life may increase risk of patent ductus arteriosus in extremely low birth weight infants. J Perinatol. 2008 Feb;28(2):123-8. Epub 2007 Nov 29.

  15. Brion LP, Soll RF. Diuretics for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD001454.

  16. Jobe AJ. The new BPD: an arrest of lung development. Pediatr Res 1999;46:641–3.

  17. Crowther CA, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD003935.

  18. Bevilacqua E, Brunelli R, Anceschi MM. Review and metaanalysis: Benefits and risks of multiple courses of antenatal corticosteroids. J Matern Fetal Neonatal Med. 2010 Apr; 23(4):244-60.

  19. Biniwale MA, Ehrenkranz RA. The role of nutrition in the prevention and management of bronchopulmonary dysplasia.Semin Perinatol. 2006 Aug; 30(4):200-8.

  20. Chorne N, Leonard C, Piecuch R, Clyman RI Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics. 2007 Jun; 119(6):1165-74.

  21. Madan JC, Kendrick D, Hagadorn JI, Frantz ID 3rd; National Institute of Child Health and Human Development Neonatal Research Network. Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome. Pediatrics. 2009 Feb; 123(2):674-81.

  22. Halliday HL, Ehrenkranz RA, Doyle LW. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD001146.

  23. Halliday HL, Ehrenkranz RA, Doyle LW. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD001145.

  24. Onland W, Offringa M,De Jaegere A, Van Kaam A. Finding the Optimal Postnatal Dexamethasone Regimen for Preterm Infants at Risk of Bronchopulmonary Dysplasia: A Systematic Review of Placebo-Controlled Trials. Pediatrics 2009;123:367.

  25. Jobe,A. The Search for Treatment of Bronchopulmonary Dysplasia. JAMA Pediatrics2016 Vol:170 Nro:4 Págs:322-4.

  26. Manktelow BN, Draper ES, Annamalai S, Field D. Factors affecting the incidence of chronic lung disease of prematurity in 1987, 1992, and 1997. Arch Dis Child 2001;85:F33-5.

  27. Fok TF. Adjunctive pharmacotherapy in neonates with respiratory failure. Seminars in Fetal Neonatal Medicine 2009; 14: 49–55

  28. Thomas W. Speer CP. Nonventilatory Strategies for Prevention and Treatment of Bronchopulmonary Dysplasia–What Is the Evidence? Neonatology 2008;94:150–159.

  29. Brion LP, Primhak RA. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2002;(1).CD001453.

  30. Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev 2007;(4):CD000501.

  31. Ambalavanan N, Tyson JE, Kennedy KA, Hansen NI, Vohr BR, Wright LL, Carlo WA; National Institute of Child Health and Human Development Neonatal Research Network. Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. Pediatrics. 2005 Mar; 115(3):e249-54. Epub 2005 Feb 15

  32. Kaplan HC, Tabangin ME, McClendon D, Meinzen-Derr J, Margolis PA, Donovan EF. Understanding Variation in Vitamin A Supplementation Among NICUs. Pediatrics. 2010 Jul 5. [Epub ahead of print]

  33. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006;354(20):2112–21.

  34. Caffeine versus theophylline for apnea in preterm infants. Henderson-Smart DJ, Steer PA. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD000273.

  35. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W; Caffeine for Apnea of Prematurity Trial Group. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007 Nov 8;357(19):1893-902.

  36. Fok TF. Adjunctive pharmacotherapy in neonates with respiratory failure. Seminars in Fetal Neonatal Medicine 2009;14:49–55.

  37. Ng GY, Da S, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev 2001;( 3).CD003214




2020     |     www.medigraphic.com